ZEB2 and breast cancer: Perhaps consistent with this, breast cancers expressing higher levels of the epithelium-promoting miR-200 family that represses the CDH1-suppressing EMP drivers ZEB1 and ZEB2 have poorer outcomes; however, this appeared to be due to mechanisms additional to E-cadherin regulation [86].